Pulmonary Vein Isolation Versus Left Atrial Posterior Wall Isolation with the Cryoballoon Using the Cross-Over Technique in Persistent Atrial Fibrillation

Fuminori Odagiri, Takashi Tokano, Tetsuro Miyazaki, Koji Hirabayashi, Kai Ishi, Hiroshi Abe, Sayaki Ishiwata, Midori Kakihara, Masaaki Maki, Hiroki Matsumoto, Ryosuke Shimai, Tadao Aikawa, Shintaro Takano, Yuki Kimura, Shunsuke Kuroda, Hiroyuki Isogai, Dai Ozaki, Tomoyuki Shiozawa, Yuki Yasuda, Kiyoshi Takasu, Kenichi Iijima, Kazuhisa Takamura, Tomomi Matsubara, Haruna Tabuchi, Hidemori Hayashi, Ken Yokoyama, Gaku Sekita, Masataka Sumiyoshi, Yuji Nakazato, Tohru Minamino
doi: https://doi.org/10.1101/2024.03.04.24303746

Abstract

Background The cryoballoon (CB) has recently been used for performing pulmonary vein isolation (PVI) with concomitant left atrial posterior wall isolation (LAPWI). However, successful LAPWI using only the CB is technically challenging. This study aimed to evaluate the feasibility, safety, and efficacy of the cross-over technique, wherein an overlapped ablation is performed by placing the CB from both left and right directions in contact with the roof and bottom of the left atrium (LA).

Methods This was a single-center, retrospective, observational study of 194 consecutive patients with persistent atrial fibrillation (PerAF) who underwent a first-time procedure of PVI + PWI (108 patients) or PVI-only (86 patients) using the CB between April 2021 and December 2023. The cross-over technique was applied in all LAPWI using the CB.

Results For ablation of the LA roof and bottom, respectively, a mean of 8.6 ± 1.0 (L→R 4.3 ± 1.1 and R→L 4.3 ± 1.1) and 9.1 ± 1.2 (L→R 4.5 ± 1.2 and R→L 4.6 ± 1.6) CB applications were delivered. LAPW was successfully isolated solely using CB in 107 patients (99.1%). The PVI + PWI group, compared to the PVI-only group, had significantly longer procedure time (180.0 ± 42.4 vs. 78.0 ± 22.1 min, P < 0.001). No severe adverse events were observed in either group. During a median follow-up of 19 months, 93.5% and 72.9% of the PVI + PWI and PVI-only groups, respectively, were free from all atrial tachyarrhythmia recurrence (P = 0.011). Cox regression analyses showed LA diameter and PVI + PWI were independent predictors of all atrial tachyarrhythmias recurrence.

Conclusions LAPWI performed solely with the CB using the cross-over technique is feasibly, safe, and was independently associated with a significantly higher freedom from recurrence of atrial tachyarrhythmias compared with PVI alone on midterm follow-up in patients with PerAF.

WHAT IS KNOWN?

  • The cryoballoon (CB) has recently been used for performing pulmonary vein isolation (PVI) with concomitant left atrial posterior wall isolation (LAPWI). LAPWI using the CB was previously demonstrated to be superior to PVI alone for the treatment of persistent atrial fibrillation (PerAF).

  • However, successful LAPWI using only the CB is technically challenging, and there is no established LAPWI technique or protocol using the CB.

WHAT THE STUDY ADDS?

  • LAPWI solely with the CB was successfully performed using the cross-over technique, wherein an overlapped ablation was performed placing the CB from both left to right and right to left directions in contact with the roof and bottom of the LA.

  • This technique achieved a high rate of acute success (99.1%) and freedom from recurrence of atrial tachyarrhythmias (93.5%) on a midterm follow-up without increasing adverse events.

  • The cross-over technique could be considered an effective ablation strategy for LAPWI, especially in difficult cases such as narrow and steeply angled LA roof and bottom.

Introduction

Pulmonary vein isolation (PVI) is the primary strategy of catheter ablation for treating atrial fibrillation (AF)1, and it is particularly effective for paroxysmal AF2. However, PVI alone has limited efficacy in patients with persistent AF (PerAF)3, despite the use of numerous ablation techniques4. An optimal additional lesion set has not been established5.

The posterior wall of the left atrium (LA) is a target for catheter ablation6. The posterior wall of the LA is embryologically related to the pulmonary veins and is responsible for the initiation and maintenance of AF7. Richardson et al8. reported several reasons why the combination of PVI and posterior wall isolation (PWI) is an attractive lesion set. First, isolation of the entire posterior wall has been associated with improved outcomes9. Second, PWI creates a conduction block to prevent potential reentrant circuits. Third, PWI reinforces PVI by reducing the potential for small gaps in the posterior aspect of the PVI lesion set, leading to PV conduction recovery. Fourth, PWI debulks the potential substrate or trigger sites for AF initiation or perpetuation, since the posterior wall is histologically similar to PV tissue10, 11. Finally, PWI may more reliably lead to ablation of the ganglionated plexi.

The cryoballoon (CB) has recently been used for performing PVI with concomitant LAPWI, and several studies have shown that LAPWI using the CB is superior to PVI alone for the treatment of PerAF12–16. However, successful LAPWI using only the CB is technically challenging, with reported success rates ranging from 54% to 84%17. Moreover, no LAPWI technique and protocol using the CB has been formally established.

To address these issues for LAPWI using the CB, we devised the cross-over technique, wherein an overlapped ablation was performed placing the CB from both left to right and right to left directions in contact with the roof and bottom of the LA. This study aimed to evaluate the feasibility, safety, and efficacy of this approach for LAPWI compared with PVI alone in patients with PerAF.

Methods

Study population

This was a single-center retrospective observational study that included 194 consecutive patients with PerAF (lasting more than 7 days) who underwent a first-time procedure of PVI + PWI (108 patients) or PVI-only (86 patients) between April 2021 and December 2023. Additional LAPWI was performed at the discretion of the physician. Prior ablation of right atrial arrhythmia was permitted. The exclusion criteria included patients younger than 18 years, paroxysmal AF (terminated within 7 days), sustained atrial fibrillation lasting more than 3 years, prior left atrial ablation (catheter or surgically based), cerebral ischemic events, myocardial infarction, or unstable angina in the previous 2 months, intracavitary thrombus, significant valvular disease, corrected or uncorrected congenital heart disease, a left atrial diameter of 60 mm or greater, chronic kidney disease requiring dialysis, pregnancy, contraindications to general anesthesia, life expectancy less than 1 year, contraindications to oral anticoagulants (OACs), clinical follow-up less than 3 months, and inability to provide informed consent. The study protocol was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee of our institution. All patients provided written informed consent.

Preprocedural management

Patient demographics were recorded at baseline. A transthoracic echocardiogram (TTE) was performed within 1 year before the procedure to assess structural heart disease. Antiarrhythmic drugs (AADs) were discontinued for longer than five half-lives before the procedure. Amiodarone was discontinued at least one month before the procedure when possible, at the attending cardiologist’s discretion. A transesophageal echocardiogram (TEE) was performed to exclude the presence of thrombi the day before the procedure. Contrast-enhanced multidetector cardiac computed tomography was performed before the procedure to assess detailed LA and PV anatomy. All patients received OACs for 3 weeks or longer before the procedure, and these drugs were not interrupted (warfarin and dabigatran) or were temporarily switched to dabigatran (rivaroxaban, apixaban, and edoxaban) for the procedure.

Procedure, PVI

All procedures were performed under moderate sedation with dexmedetomidine, bolus injection of pentazocine and thiopental as needed, and a nasal mask for noninvasive mechanical ventilation. After obtaining vascular access, heparin (100 IU/kg body weight) was administered. Two transseptal catheters are necessary for mapping and catheter ablation in LAPWI. Accordingly, a single (PVI-only) or double (PVI + PWI) transseptal puncture was performed as needed with an RF needle (Baylis Medical, Inc, Montreal, Canada) guided by fluoroscopy and intracardiac echocardiography (ViewFlex, Abbott, St. Paul, MN, USA). After obtaining LA access, the activated clotting time was maintained at ≥ 300 seconds by heparin infusion.

In all study patients, a fourth-generation 28-mm CB catheter (Arctic Front Advance PRO; Medtronic), was introduced into the LA through a steerable sheath (FlexCath Advance Medtronic Inc, 15Fr), and an inner lumen mapping catheter (Achieve, Medtronic Inc, Minneapolis, MN, USA) was positioned in each PV ostium. The CB was advanced, inflated, and positioned at the ostium of each PV. After achieving optimal PV occlusion, as assessed by venous angiography, 1–2 CB applications were delivered for 180–240 s to each PV based on previous reports18, 19. Regarding the ablation sequence, the left superior PV (LSPV) was treated first, followed by the left inferior PV (LIPV), the right superior PV (RSPV), and then by the right inferior PV (RIPV) (Figure 1).

Figure 1.
Figure 1.

Representative AP fluoroscopic images of the left atriography and the CB position of during PVI. The LA roof and bottom were indicated by the yellow dotted lines. AP, anteroposterior; CB, cryoballoon; PVI, pulmonary vein isolation; LA, left atrial; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein.

To avoid esophageal damage and gastric hypomotility (GH), the luminal esophageal temperature (LET) was monitored throughout ablation. CB applications were interrupted in case of LET ≤ 18℃. To prevent phrenic nerve (PN) injury, the diaphragmatic compound motor action potentials (CMAP) were monitored during PN pacing from an electrode in the right subclavian vein or superior vena cava during CB application of the right PVs. The CB application was immediately terminated if the maximum voltage of the CMAP decreased by 30% from baseline or if the diaphragmatic excursions weakened. Successful PVI was defined as a bidirectional block between PV and LA using an inner lumen mapping catheter (PVI-only) or a circular mapping catheter (Abbott Laboratories, Chicago, IL, USA) (PVI + PWI). No additional CB applications were delivered after PVI. If a successful PVI was not achieved, additional touch-up ablation was performed using an irrigated radiofrequency (RF) catheter (FlexAbilityTM, Abbott, Chicago, IL, USA).

Procedure, LAPWI

Once PVI was completed, CB was used to perform LAPWI. When LA roof area ablation was performed, the Achieve catheter was placed deeply in the LSPV to stabilize the CB, which was shifted clockwise along the LA roof by adjusting the bending of the steerable sheath to apply pressure. The LA roof area was divided into 4 segments from left to right guided by fluoroscopic images in the anteroposterior (AP) view, L1, L2, L3, and L4, toward the right superior PV (Figure 2). The CB was positioned such that each location overlapped with one-third of the previous site. A single 120-s CB application was delivered at each site.

Figure 2.
Figure 2.

Representative AP fluoroscopic images of the left atriography, LA roof area, LA bottom area, and LPV carina ablation. The LA roof and bottom were divided into 4 segments from left to right guided by fluoroscopic images in the AP view, L1, L2, L3, and L4, toward the right side superior and inferior PV, respectively. The LA roof and bottom were indicated by the yellow dotted lines. AP, anteroposterior; LA, left atrial; LPV, left pulmonary vein; PV, pulmonary vein.

When LA bottom area ablation was performed, the Achieve catheter was deeply placed in the LIPV, and the CB was shifted clockwise along the LA bottom by adjusting the bending of the steerable sheath to apply pressure. The LA bottom area was also divided into 4 segments from left to right guided by fluoroscopic images in the AP view, L1, L2, L3, and L4, toward the right inferior PV (Figure 2). The left pulmonary vein (LPV) carina was routinely ablated with a single 180-s CB application by anchoring the achieve catheter in the LSPV, bending the steerable sheath (similar to when ablating the LIPV), and contacting the CB in a direction from the LSPV to the LIPV (Figure 2).

After the LAPW was ablated from left to right, the Achieve catheter was placed deeply in the RSPV, and the CB was shifted counterclockwise along the LA roof by adjusting the bending of the steerable sheath to apply pressure. The LA roof area was divided into 4 segments from right to left guided by fluoroscopic images in the AP view, R1, R2, R3, and R4, toward the left superior PV (Figure 3). CB ablation of the LA bottom area and right pulmonary vein (RPV) carina were performed in the same manner from the right side with the Achieve catheter positioned in the inferior and superior PV, respectively (Figure 3); this was the cross-over technique.

Figure 3.
Figure 3.

Representative AP fluoroscopic images of the left atriography, LA roof area, LA bottom area, and RPV carina ablation. The LA roof and bottom were divided into 4 segments from right to left guided by fluoroscopic images in the AP view, R1, R2, R3, and R4, toward the left side superior and inferior PV, respectively. The LA roof and bottom were indicated by the yellow dotted lines. AP, anteroposterior; LA, left atrial; RPV, right pulmonary vein; PV, pulmonary vein.

The LET was monitored throughout ablation, and temperatures ≤ 18℃ were avoided. CB applications were resumed once the LET returned to baseline. To prevent PN injury, CMAP was monitored during PN pacing from an electrode in the right subclavian vein or superior vena cava during CB ablation of the roof in R1, bottom in R1, and RPV carina.

Once completed, LAPWI was confirmed by creating voltage maps and using high output pacing (10V) with a circular mapping catheter to test for entrance or exit block (Figure 4-1 and 2). Whenever LAPWI could not be achieved between 1–2 additional applications using the CB alone at each site, additional touch-up ablation was performed using an irrigated RF catheter (FlexAbilityTM, Abbott, Chicago, IL, USA). All procedures were performed by a single operator (F.O) skilled in this technique.

Figure 4-1 and 2.
Figure 4-1 and 2.
Figure 4-1 and 2.

Representative voltage maps of the pre ablation (A), post PVI-only (B), and post PVI + LAPWI (C) recorded with the three-dimensional mapping with the EnSite Velocity system and AdvisorTM VL Circular Mapping Catheter (Abbott Laboratories, Chicago, IL, USA), voltage settings were 0.2 to 0.5mV. The purple region represented the voltages greater than 0.5mV and the gray region represented the voltages less than 0.2mV. PVI, pulmonary vein isolation; LAPWI, left atrial posterior wall isolation.

Postprocedural management and Follow-up

After the procedure, patients were continuously monitored via telemetry until discharge, which was usually on the 2nd postprocedural day. Previous prescriptions of AADs were resumed after the procedure at the discretion of the attending cardiologist. The patients were followed-up at our institution 1 month after ablation and every 2–3 months thereafter, or whenever patients experienced symptoms. A 12-lead electrocardiogram (ECG) was recorded at each visit to the outpatient clinic, and 24-h Holter ECG monitoring was performed at 3, 6, 12, and 24 months after the procedure. Recurrence was defined as any symptomatic or asymptomatic episode of atrial tachyarrhythmia (AF, atrial tachycardia [AT], or atrial flutter) lasting >30 s after the 3-month blanking period.

Statistical analysis

Continuous data are expressed as the mean ± standard deviation for normally distributed variables or as the median with the interquartile range for non-normally distributed variables. Categorical variables are presented as numbers and percentages. Statistical comparisons were performed using Student’s t-test or Chi-square test, as appropriate. The analysis of the time-to-first event was described using Kaplan–Meier estimates; groups were compared using the log-rank test. All statistical analyses were performed using SPSS (version 29.0; IBM Company, Chicago, IL, USA), with P < 0.05 indicating statistical significance.

Results

Baseline characteristics

The baseline patient characteristics are shown in Table 1. In the PVI + PWI group, the mean age was 65.9 ± 10.5 years, 83 patients (76.9%) were male, and the median AF duration was (interquartile range: 3.0–10.0) months. There were no significant differences between the PVI + PWI and PVI-only groups in these parameters. The mean CHADS2 score, CHA2DS2-VASc score, and HAS-BLED score tended to be low in both groups. The mean left ventricular ejection fraction and mean LA diameter by echocardiography were 59.6 ± 11.3% and 43.5 ± 5.3mm, respectively, in the PVI + PWI group. There was no significant difference in each parameter between the PVI + PWI and PVI-only groups.

View this table:
Table 1. Baseline patient characteristic

Procedural results

The procedural-related data are shown in Table 2. Acute PVI was achieved in all patients with CB without the need for touch-up RF ablation. The mean number of CB applications required for PVI was 5.2 ± 1.2, the mean total ablation time to achieve PVI was 14.9 ± 3.1 minutes, the mean minimum CB temperature reached to achieve PVI was −55.2℃ ± 3.7℃, and additional cavotricuspid isthmus (CTI) ablation was performed in 112 patients (57.7%), all of which had a confirmed CTI bidirectional block. The PVI + PWI group, compared to the PVI-only group, had significantly longer procedure time (180.0 ± 42.4 vs. 78.0 ± 22.1 min, P < 0.001) and fluoroscopy time (53.1 ± 17.4 vs. 21.3 ± 6.7 min, P < 0.001).

View this table:
Table 2. Procedural-related data and postprocedural AADs therapy

LAPW was successfully isolated solely with the CB using the cross-over technique except for one case (99.1%). The level of serum creatine kinase (CK) the day after the procedure and the ratio of CK the day after to the day before the procedure were significantly higher in the PVI + PWI group than in the PVI-only group (550.2 ± 280.6 vs. 379.2 ± 206.9 IU/l, P < 0.001; 6.1 ± 4.7 vs. 3.2 ± 1.7, P < 0.001, respectively).

LAPW isolation

The procedural characteristics of LAPWI are shown in Table 3. The mean number of CB applications was 8.6 ± 1.0 (L→R 4.3 ± 1.1 and R→L 4.3 ± 1.1) for LA roof ablation and 9.1 ± 1.2 (L→R 4.5 ± 1.2 and R→L 4.6 ± 1.6) for LA bottom ablation. The mean minimum CB temperature was −40.8℃ ± 5.4℃ (L→R −41.2℃ ± 5.7℃ and R→L −40.5℃ ± 4.7℃) during LA roof ablation (Figure 5A and 5C) and −37.8℃ ± 5.1℃ (L→R −37.9℃ ± 4.9℃ and R→L −37.7℃ ± 4.9℃) during LA bottom ablation (Figure 5B and 5D).

Figure 5.
Figure 5.

The mean minimum CB temperature at each site during the LA roof area (from left to right [A] and right to left [C] sides), LA bottom area (from left to right [B] and right to left [D] sides) and PV carinas (E) ablation. Data are mean ± standard deviation.

View this table:
Table 3. Procedural characteristics of LAPWI

LPV and RPV carinas were ablated using CB in all patients in the PVI + PWI group. A mean number of 2.0 ± 0.0 CB applications (LPV 1.0 ± 0.0 and RPV 1.0 ± 0.0) was delivered for PV carina ablation. The mean minimum CB temperature during PV carina ablation was −41.7℃ ± 6.9℃ (LPV −43.2℃ ± 7.8℃ and RPV −40.2℃ ± 5.4℃) (Figure 5E). A mean number of 19.3 ± 1.6 CB applications was delivered for LAPW isolation (roof, bottom, and both PV carinas). The mean minimum CB temperature for total LAPW ablation was −39.5℃ ± 5.7℃ (Table 3). LAPW was successfully isolated solely using the CB in 107 out of 108 patients (99.1%), whereas the LAPW was completed by additional touch-up RF ablation in 1 patient (Table 2).

Complications

The safety endpoints are shown in Table 2. The overall adverse event rate was low, with no significant difference between the PVI + PWI and PVI-only groups (1.9% vs. 2.3%, P = 0.818). Transient PN palsy occurred in 2 patients (1.9%) in the PVI + PWI group and 1 patient (1.2%) in the PVI-only group, with complete resolution within 6 months after the procedure. No PN palsy occurred during LA roof, bottom, or PV carina ablation. One patient (1.2%) in the PVI-only group developed an arteriovenous fistula which required surgical repair. No other severe periprocedural complications, such as death, stroke, cardiac tamponade, or GH, were observed.

Follow-up

AADs were resumed in 109 out of 194 (56.2%) patients at discharge (PVI + PWI group, 52.8%; PVI-only group, 60.5%; P = 0.284) and maintained in 51 out of 194 (26.3%) patients after the 3-month blanking period (PVI + PWI group, 23.1%; PVI-only group, 30.2%; P = 0.266) (Table 2). During a median follow-up of 19 (interquartile range: 14–27) months, all enrolled patients completed the study protocol. During the follow-up period, freedom from recurrence of all atrial tachyarrhythmias was achieved in 93.5% (101/108) of the PVI + PWI group and 72.9% (69/86) of the PVI-only group (Figure 6A). Specifically, freedom from AF recurrence was seen in 96.3% (104/108) of the PVI + PWI group and 72.9% (69/86) of the PVI-only group (Figure 6B). On the other hand, freedom from AT recurrence was seen in 97.2% (105/108) of the PVI + PWI group and 100% (86/86) of the PVI-only group (Figure 6C). LAPWI was associated with a significantly lower rate of midterm recurrence of all atrial tachyarrhythmias (log-rank P = 0.011), particularly AF (log-rank P = 0.001), compared with PVI-only (Figure 6A and 6B).

Figure 6.
Figure 6.

Kaplan-Meier Curves illustrating cumulative freedom from midterm recurrence of all atrial tachyarrhythmias (A), atrial fibrillation (B), and atrial tachycardias (C) after the procedure in the PVI + PWI group and in the PVI-only group, including the number of patients at risk. BP, blanking period.

Univariate and multivariate Cox regression analyses to identify the potential risk factors for the recurrence of all atrial tachyarrhythmias are shown in Table 4. After adjusting for confounding factors, LA diameter (hazard ratio [HR] 1.103, 95% confidence interval [CI] 1.005–1.211; P = 0.038) and PVI + PWI (HR 0.359, 95% CI 0.138–0.931; P = 0.035) were independent predictors of all atrial tachyarrhythmias recurrence.

View this table:
Table 4. Predictors of all atrial tachyarrhythmias recurrence in a Cox regression analysis

Discussion

Although the CB catheter is designed for single-shot PVI20, several studies have reported that PVI with concomitant LAPWI using the CB is superior to PVI alone for the treatment of PerAF 12–16, but no formal protocol has been established. To the best of our knowledge, this is the first study to describe the feasibility, safety, and efficacy of PVI with concomitant LAPWI solely with the CB using the cross-over technique. Our key findings are as follows: (1) complete LAPWI solely with the fourth-generation 28-mm CB catheter using the cross-over technique was achieved in 99.1% of PerAF patients; (2) PVI with concomitant LAPWI using the CB did not increase procedure-related complications; (3) the rate of midterm recurrence of atrial tachyarrhythmias was significantly lower in the PVI + PWI group than in the PVI-only group.

Nishimura et al. demonstrated that having an LA roof angle (i.e., the anatomical angle of the bucking point of the LA roof formed by the left-sided and right-sided roof) less than 115° predicted unsuccessful construction of an LA roof blockline because of the difficulty in ensuring optimal CB contact at the bucking point of a relatively narrow-angled LA roof13. Although this study had 6 patients (5.6%) with an LA roof angle < 115° in the PVI + PWI group, we were able to successfully construct an LA roof blockline solely with the CB using the cross-over technique in all patients of the PVI + PWI group. It was also difficult to ensure optimal CB contact with the concave and steep-angled LA bottom compressed by vertebral bodies. Nevertheless, we were able to successfully construct the LA bottom blockline in the PVI + PWI group solely with the CB using the cross-over technique, except for one case. The mean angle of the LA bottom was 140.0 ± 13.3° in the PVI + PWI group, whereas the unsuccessful case had the steepest angle of 103°. Thus, the cross-over technique could be considered an effective ablation strategy for difficult cases such as narrow and steeply angled LA roof and bottom, because this technique involves overlapping ablations by placing the CB from both left to right and right to left directions in contact with the roof and bottom of the LA.

Miyazaki et al30. reported that maneuverability for additional PWI might be superior with the fourth-generation versus the second-generation CB because of its relatively shorter tip length. Previous reports of LAPWI using the CB for PerAF have used the second-generation CB12–16. However, the fourth-generation CB was used in all patients in this study; its shorter balloon tip likely enabled optimal with the LA roof and bottom area, which might have also led to the high rates of acute success and freedom from atrial tachyarrhythmia recurrence.

Previous studies utilized a series of overlapping 120–240 s CB applications at each site during LAPWI13–15. In this study, 120-s CB applications were delivered at each site for LA roof and bottom ablation, while 180-s CB applications were delivered for PV carina ablation. Having a longer CB application time correlates with deeper lesions, leading to increased lesion durability21. However, it may also be associated with an increased risk of collateral damage to extracardiac structures, such as the PN and esophagus22–24. Esophageal thermal injury, which can lead to more serious conditions such as GH and left atrial-esophageal fistula, is a potential complication after LAPWI25, 26. Previous studies have reported that esophageal thermal injury rates associated with CB ablation ranged from 3.2% to 19% seen on postprocedural esophagogastroduodenoscopy (EGD)27, 28. In addition, Miyazaki et al. reported that the incidence of symptomatic GH was 0.23%29. In this study, no serious esophageal thermal injury such as symptomatic GH was observed, although mild esophageal lesions might have been missed because postprocedural EGD was not performed.

In areas where sufficient application time could not be secured due to the LET dropping below 18℃, CB application can often be achieved without reaching the LET of 18℃ or less by anchoring it from the opposite side, even if the balloon location is almost the same position under fluoroscopy. This is possible because the direction of force transmission is different when anchoring from the left and the right side; this is one of the benefits of the cross-over technique.

A single 120-s CB application might be insufficient for lesion formation and durability at each site. However, the cross-over technique allows for sequential overlapping freezes from both the left and right sides. This may have a beneficial impact on the efficacy and safety of LAPWI using the CB.

It is important not only to construct the horizontal block lines of the LA roof and bottom but also the vertical block lines consisting of the PV and PV carina to ensure durability of the LAPWI. Accordingly, LPV and RPV carinas were routinely ablated in addition to the 4 PVs, LA roof, and LA bottom in this study; this may have contributed to the high rate of freedom from atrial tachyarrhythmia recurrence.

A redo ablation procedure was performed in 3 out of 7 patients exhibiting atrial tachyarrhythmia recurrence in the PVI + PWI group. Two patients had a recurrence of AF and the other patient had a recurrence of AT. The patients with AF recurrence were confirmed to have reconnection at the LSPV (and CTI) and RIPV, respectively, and the patient with AT recurrence was confirmed at the perimitral AT. These three patients were also confirmed to have no reconnection at the LA roof, LA bottom, and both PV carinas. On the other hand, Shigeta et al14. reported that LA roof and bottom-line ablation performed using the CB demonstrated durability in 72.5% and 48.3% of patients, respectively, at the beginning of the redo ablation procedure.

The lower durability of LA bottom ablation versus that of LA roof ablation using the CB is due to the difficulty in ensuring the optimal contact of the distal hemisphere of the CB to the LA bottom. In addition, inadequate CB contact due to the steep-angled LA bottom and insufficient application time due to reaching the LET cut-off value might also be contributory. The cross-over technique for LAPWI using the CB could be effective against any of these challenging factors. Although further studies are required to evaluate the durability of the LAPWI performed with the CB using the cross-over technique, it can potentially improve the acute success rate and durability of LAPWI.

The number of CB applications in the PVI + PWI group led to significantly longer procedure and fluoroscopy times and significantly higher postprocedural CK levels versus the PVI-only group. However, no severe adverse events associated with these factors (e.g., radiodermatitis and pericarditis) were observed.

Limitations

Several limitations of this study should be acknowledged. First, this was a single-center, non-randomized, retrospective, observational study with a relatively small study population. Even if all variables were balanced between the two groups, selection bias cannot be excluded. Second, esophageal damage might have been underestimated because EGD was not performed after the procedure. Third, despite the absence of a significant difference in AAD therapy between the two groups, this was still maintained in 26.3% of patients after the 3-month blanking period, which may have influenced our findings. Fourth, the rate of symptomatic and asymptomatic atrial tachyarrhythmia recurrence might have been underestimated, because no long-term monitoring was done (i.e., using an event recorder). Lastly, all procedures were performed by a single operator who was experienced in the cross-over technique, and thus these results may be dependent on the skill of the operator. Further studies, including multicenter and large populations, are needed to confirm the general usefulness of this ablation technique.

Conclusions

Despite having significantly longer procedure and fluoroscopy times, LAPWI performed solely with the CB using the cross-over technique is feasibly, safe, and independently associated with a significantly higher freedom from recurrence of atrial tachyarrhythmias compared with PVI alone on midterm follow-up in patients with PerAF. This technique can potentially improve the acute success rate and durability of LAPWI.

Data Availability

Raw data were generated at Juntendo University Urayasu Hospital. Derived data supporting the findings of this study are available from the corresponding author [FO] on request.

Sources of Funding

None.

Disclosures

None.

Non-standard Abbreviations and Acronyms

CB
cryoballoon
PVI
pulmonary vein isolation
LAPWI
left atrial posterior wall isolation
LA
left atrium
PerAF
persistent atrial fibrillation
OACs
oral anticoagulants
TTE
transthoracic echocardiogram
AADs
antiarrhythmic drugs
GH
gastric hypomotility
LET
luminal esophageal temperature
PN
phrenic nerve
CMAP
compound motor action potentials
RF
radiofrequency
AP
anteroposterior
ECG
electrocardiogram
AT
atrial tachycardia
CTI
cavotricuspid isthmus
CK
creatine kinase
EGD
esophagogastroduodenoscopy

References

  1. 1.↵
    Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 Sep 3;339(10):659–66. doi: 10.1056/NEJM199809033391003.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Köktürk B, Konstantinidou M, Metzner A, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010 Dec 7;122(23):2368–77. doi: 10.1161/CIRCULATIONAHA.110.946806. Epub 2010 Nov 22.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Brooks AG, Stiles MK, Laborderie J, Lau DH, Kuklik P, Shipp NJ, Hsu LF, Sanders P. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm 2010 Jun;7(6):835–46. doi: 10.1016/j.hrthm.2010.01.017. Epub 2010 Jan 22.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Ciconte G, Baltogiannis G, de Asmundis C, Sieira J, Conte G, Di Giovanni G, Saitoh Y, Irfan G, Mugnai G, Hunuk B, et al. Circumferential pulmonary vein isolation as index procedure for persistent atrial fibrillation: a comparison between radiofrequency catheter ablation and second-generation cryoballoon ablation. Europace 2015 Apr;17(4):559–65. doi: 10.1093/europace/euu350. Epub 2015 Jan 12.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015 May 7;372(19):1812–22. doi: 10.1056/NEJMoa1408288.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Sugumar H, Thomas SP, Prabhu S, Voskoboinik A, Kistler PM. How to perform posterior wall isolation in catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2018 Feb;29(2):345–52. doi: 10.1111/jce.13397. Epub 2017 Dec 26.
    OpenUrlCrossRef
  7. 7.↵
    Lee SH, Tai CT, Hsieh MH, Tsao HM, Lin YJ, Chang SL, Huang JL, Lee KT, Chen YJ, Cheng JJ, et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation. J Am Coll Cardiol 2005 Sep 20;46(6):1054–9. doi: 10.1016/j.jacc.2005.06.016.
    OpenUrlFREE Full Text
  8. 8.↵
    Richardson T, Michaud GF. Using the cryoballoon for posterior wall isolation: thinking inside “the box”. Heart Rhythm 2018 Aug;15(8):1130–1. doi: 10.1016/j.hrthm.2018.05.015.
    OpenUrlCrossRef
  9. 9.↵
    Voeller RK, Bailey MS, Zierer A, Lall SC, Sakamoto S, Aubuchon K, Lawton JS, Moazami N, Huddleston CB, Munfakh NA, et al. Isolating the entire posterior left atrium improves surgical outcomes after the Cox maze procedure. J Thorac Cardiovasc Surg 2008 Apr;135(4):870–7. doi: 10.1016/j.jtcvs.2007.10.063. Epub 2008 Mar 18.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Cabrera JA, Ho SY, Climent V, Fuertes B, Murillo M, Sánchez-Quintana D. Morphological evidence of muscular connections between contiguous pulmonary venous orifices: relevance of the interpulmonary isthmus for catheter ablation in atrial fibrillation. Heart Rhythm 2009 Aug;6(8):1192–8. doi: 10.1016/j.hrthm.2009.04.016. Epub 2009 Apr 15.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Ho SY, Cabrera JA, Sanchez-Quintana D. Left atrial anatomy revisited. Circ Arrhythm Electrophysiol 2012 Feb;5(1):220–8. doi: 10.1161/CIRCEP.111.962720.
    OpenUrlFREE Full Text
  12. 12.↵
    Aryana A, Baker JH, Espinosa Ginic MA, Pujara DK, Bowers MR, O’Neill PG, Ellenbogen KA, Di Biase L, d’Avila A, Natale A. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: a multicenter experience. Heart Rhythm 2018 Aug;15(8):1121–9. doi: 10.1016/j.hrthm.2018.05.014.
    OpenUrlCrossRef
  13. 13.↵
    Nishimura T, Yamauchi Y, Aoyagi H, Tsuchiya Y, Shigeta T, Nakamura R, Yamashita M, Asano M, Nakamura T, Suzuki H, et al. The clinical impact of the left atrial posterior wall lesion formation by the cryoballoon application for persistent atrial fibrillation: feasibility and clinical implications. J Cardiovasc Electrophysiol 2019 Jun;30(6):805-doi: 10.1111/jce.13879. Epub 2019 Feb 23.
    OpenUrlCrossRef
  14. 14.↵
    Shigeta T, Yamauchi Y, Sagawa Y, Oda A, Tachibana S, Sudo K, Nakamura R, Okishige K, Goya M, Sasano T. Cryoballoon ablation of the left atrial posterior wall reduces recurrence of persistent atrial fibrillation in patients with non-paroxysmal atrial fibrillation. J Arrhythm 2021 Nov 5;37(6):1477–87. doi: 10.1002/joa3.12654
    OpenUrlCrossRef
  15. 15.↵
    Aryana A, Allen SL, Pujara DK, Bowers MR, O’Neill PG, Yamauchi Y, Shigeta T, Vierra EC, Okishige K, Natale A. Concomitant pulmonary vein and posterior wall isolation using cryoballoon with adjunct radiofrequency in persistent atrial fibrillation. JACC Clin Electrophysiol 2021 Feb;7(2):187–96. doi: 10.1016/j.jacep.2020.08.016. Epub 2020 Oct 28.
    OpenUrlCrossRef
  16. 16.↵
    Ahn J, Shin DG, Han SJ, Lim HE. Does isolation of the left atrial posterior wall using cryoballoon ablation improve clinical outcomes in patients with persistent atrial fibrillation? A prospective randomized controlled trial. Europace 2022 Jul 21;24(7):1093–101. doi: 10.1093/europace/euac005.
    OpenUrlCrossRef
  17. 17.↵
    Moustafa A, Liu X, Elzanaty A, Meenakshisundaram C, Kancharla K, Kahaly O, Chacko P. Role of adjunctive cryoballoon left atrial posterior wall isolation in non-paroxysmal atrial fibrillation: A meta-analysis. Curr Probl Cardiol 2022 Dec;47(12):101383. doi: 10.1016/j.cpcardiol.2022.101383. Epub 2022 Aug 31.
    OpenUrlCrossRef
  18. 18.↵
    Aryana A, Mugnai G, Singh SM, Pujara DK, de Asmundis C, Singh SK, Bowers MR, Brugada P, d’Avila A, O’Neill PG, et al. Procedural and biophysical indicators of durable pulmonary vein isolation during cryoballoon ablation of atrial fibrillation. Heart Rhythm 2016 Feb;13(2):424–32. doi: 10.1016/j.hrthm.2015.10.033. Epub 2015 Oct 28.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Aryana A, Kenigsberg DN, Kowalski M, Koo CH, Lim HW, O’Neill PG, Bowers MR, Hokanson RB, Ellenbogen KA, Cryo-DOSING Investigators. Verification of a novel atrial fibrillation cryoablation dosing algorithm guided by time-to-pulmonary vein isolation: results from the cryo-DOSING study (cryoballoon-ablation DOSING based on the assessment of time-to-effect and pulmonary vein isolation guidance). Heart Rhythm 2017 Sep;14(9):1319–25. doi: 10.1016/j.hrthm.2017.06.020. Epub 2017 Jun 15.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KRJ, Elvan A, Arentz T, Bestehorn K, Pocock SJ, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016 Jun 9;374(23):2235–45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Chen S, Schmidt B, Bordignon S, Perrotta L, Bologna F, Chun KRJ. Impact of cryoballoon freeze duration on long-term durability of pulmonary vein isolation: ICE re-map study. JACC Clin Electrophysiol 2019 May;5(5):551–9. doi: 10.1016/j.jacep.2019.03.012.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Chun KR, Fürnkranz A, Köster I, Metzner A, Tönnis T, Wohlmuth P, Wissner E, Schmidt B, Ouyang F, Kuck KH. Two versus one repeat freeze-thaw cycle(s) after cryoballoon pulmonary vein isolation: the alster extra pilot study. J Cardiovasc Electrophysiol 2012 Aug;23(8):814–9. doi: 10.1111/j.1540-8167.2012.02315.x. Epub 2012 Apr 4.
    OpenUrlCrossRefPubMed
  23. 23.
    Metzner A, Rausch P, Lemes C, Reissmann B, Bardyszewski A, Tilz R, Rillig A, Mathew S, Deiss S, Kamioka M, et al. The incidence of phrenic nerve injury during pulmonary vein isolation using the second-generation 28 mm cryoballoon. J Cardiovasc Electrophysiol 2014 May;25(5):466–70. doi: 10.1111/jce.12358. Epub 2014 Jan 30.
    OpenUrlCrossRefPubMed
  24. 24.↵
    John RM, Kapur S, Ellenbogen KA, Koneru JN. Atrioesophageal fistula formation with cryoballoon ablation is most commonly related to the left inferior pulmonary vein. Heart Rhythm 2017 Feb;14(2):184–9. doi: 10.1016/j.hrthm.2016.10.018. Epub 2016 Oct 18.
    OpenUrlCrossRef
  25. 25.↵
    Oikawa J, Fukaya H, Wada T, Horiguchi A, Kishihara J, Satoh A, Saito D, Sato T, Matsuura G, Arakawa Y, et al. Additional posterior wall isolation is associated with gastric hypomotility in catheter ablation of atrial fibrillation. Int J Cardiol 2021 Mar 1;326:103–8. doi: 10.1016/j.ijcard.2020.10.069. Epub 2020 Oct 31.
    OpenUrlCrossRef
  26. 26.↵
    Pappone C, Oral H, Santinelli V, Vicedomini G, Lang CC, Manguso F, Torracca L, Benussi S, Alfieri O, Hong R, et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 2004 Jun 8;109(22):2724–6. doi: 10.1161/01.CIR.0000131866.44650.46. Epub 2004 May 24.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Fürnkranz A, Bordignon S, Böhmig M, Konstantinou A, Dugo D, Perrotta L, Klopffleisch T, Nowak B, Dignaß AU, Schmidt B, et al. Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation. Heart Rhythm 2015 Feb;12(2):268–74. doi: 10.1016/j.hrthm.2014.10.033. Epub 2014 Nov 4.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Fürnkranz A, Bordignon S, Schmidt B, Böhmig M, Böhmer MC, Bode F, Schulte-Hahn B, Nowak B, Dignaß AU, Chun JK. Luminal esophageal temperature predicts esophageal lesions after second-generation cryoballoon pulmonary vein isolation. Heart Rhythm 2013 Jun;10(6):789–93. doi: 10.1016/j.hrthm.2013.02.021. Epub 2013 Feb 19.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    Miyazaki S, Kobori A, Jo H, Keida T, Yoshitani K, Mukai M, Sagawa Y, Asakawa T, Sato E, Yamao K, et al. Symptomatic gastroparesis after cryoballoon-based atrial fibrillation ablation: results from a large multicenter registry. Circ Arrhythm Electrophysiol 2023 Mar;16(3):e011605. doi: 10.1161/CIRCEP.122.011605. Epub 2023 Feb 6.
    OpenUrlCrossRef
  30. 30.↵
    Miyazaki S, Hasegawa K, Mukai M, Aoyama D, Nodera M, Shiomi Y, Tama N, Ikeda H, Ishida K, Uzui H, et al. The advantages and disadvantages of the novel fourth-generation cryoballoon as compared to the second-generation cryoballoon in the current short freeze strategy. J Interv Card Electrophysiol 2022 Jan;63(1):143–52. doi: 10.1007/s10840-021-00957-5. Epub 2021 Feb 11.
    OpenUrlCrossRef
Back to top
Posted March 06, 2024.
Download PDF
Data/Code
Email
Pulmonary Vein Isolation Versus Left Atrial Posterior Wall Isolation with the Cryoballoon Using the Cross-Over Technique in Persistent Atrial Fibrillation
Fuminori Odagiri, Takashi Tokano, Tetsuro Miyazaki, Koji Hirabayashi, Kai Ishi, Hiroshi Abe, Sayaki Ishiwata, Midori Kakihara, Masaaki Maki, Hiroki Matsumoto, Ryosuke Shimai, Tadao Aikawa, Shintaro Takano, Yuki Kimura, Shunsuke Kuroda, Hiroyuki Isogai, Dai Ozaki, Tomoyuki Shiozawa, Yuki Yasuda, Kiyoshi Takasu, Kenichi Iijima, Kazuhisa Takamura, Tomomi Matsubara, Haruna Tabuchi, Hidemori Hayashi, Ken Yokoyama, Gaku Sekita, Masataka Sumiyoshi, Yuji Nakazato, Tohru Minamino
medRxiv 2024.03.04.24303746; doi: https://doi.org/10.1101/2024.03.04.24303746
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area